• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $6,165 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-616 Mln

Arena Pharmaceuticals Inc (ARNA) Share Price

$99.99

As on 14-Mar-2022 09:30 EST

$0.000.00%

  • Prev Close info

    $99.99

  • Day's Openinfo

    $99.99

  • Today's Highinfo

    $99.99

  • Today's Lowinfo

    $99.99

  • Today's Volumeinfo

    --

  • 52 Week rangeinfo

    $-- - --

Please wait...

Arena Pharmaceuticals Inc (ARNA) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Arena Pharmaceuticals Inc (ARNA)
7.59 6.59 11.00 29.74 29.86 47.34 18.57
S&P BSE Sensex*
1.90 2.12 6.90 23.08 13.13 15.34 13.25
#
-- -- -- -- -- -- --
As on 14-Mar-2022  |  *As on 05-Mar-2024  |  #As on
2021
2020
2019
2018
2017
2016
2015
Arena Pharmaceuticals Inc (ARNA)
20.97 69.15 16.61 14.57 139.23 -25.26 -45.24
S&P BSE Sensex
21.99 15.75 14.38 5.87 27.91 1.95 -5.03
S&P BSE Sensex
21.99 15.75 14.38 5.87 27.91 1.95 -5.03

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Arena Pharmaceuticals Inc (ARNA) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Arena Pharmaceuticals Inc (ARNA)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Arena Pharmaceuticals Inc (ARNA)

        Pres & CEO

        Mr. Amit D. Munshi M.B.A.

        Exec. VP & CFO

        Ms. Laurie D. Stelzer

        Headquarters

        Park City, UT

        FAQs for Arena Pharmaceuticals Inc (ARNA)

        The total asset value of Arena Pharmaceuticals Inc (ARNA) stood at $ 785 Mln as on 31-Dec-21

        The share price of Arena Pharmaceuticals Inc (ARNA) is $99.99 (NASDAQ) as of 14-Mar-2022 09:30 EST. Arena Pharmaceuticals Inc (ARNA) has given a return of 29.86% in the last 3 years.

        Arena Pharmaceuticals Inc (ARNA) has a market capitalisation of $ 6,165 Mln as on 14-Mar-2022. As per Value Research classification, it is a company.

        The P/B ratio of Arena Pharmaceuticals Inc (ARNA) is 9.16 times as on 14-Mar-2022, a 2.07% premium to its peers’ median range of 2.98 times.

        Since, TTM earnings of Arena Pharmaceuticals Inc (ARNA) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Arena Pharmaceuticals Inc (ARNA) and enter the required number of quantities and click on buy to purchase the shares of Arena Pharmaceuticals Inc (ARNA).

        Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

        The CEO & director of Mr. Amit D. Munshi M.B.A.. is Arena Pharmaceuticals Inc (ARNA), and CFO & Sr. VP is Ms. Laurie D. Stelzer.

        The promoters of Arena Pharmaceuticals Inc (ARNA) have pledged 0% of the total equity as on Feb-22.

        Arena Pharmaceuticals Inc (ARNA) Ratios
        Return on equity(%)
        -70.3
        Return on capital employed(%)
        -66.98
        Debt-to-equity ratio
        0.06
        Dividend yield(%)
        --

        No, TTM profit after tax of Arena Pharmaceuticals Inc (ARNA) was $-616 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $6,165.32 Mln
        • Revenue (TTM)revenue-information $-3.48 Mln
        • Earnings (TTM) earning-information $-616.43 Mln
        • Cash date-information $550.47 Mln
        • Total Debt info $41.21 Mln
        • Insider's Holding 0.27%
        • Liquidity liquidity
        • 52 Week range week-range $-- - --
        • Shares outstanding share-outstanding 61,659,400
        • 10 Years Aggregate:

          CFO: $-668.17 Mln

          EBITDA: $-936.14 Mln

          Net Profit: $-1,040.33 Mln

        About The Company

        • IPO Date 28-Jul-2000
        • Pres & CEO Mr. Amit D. Munshi M.B.A.
        • Exec. VP & CFO Ms. Laurie D. Stelzer
        • Listing key-listing NASDAQ: ARNA
        • Country United States
        • Headquarters headquarters Park City, UT
        • Website website https://www.arenapharm.com
        • Business

          Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase...  III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.  Read more

        share-fund-plan-icon